Cargando…

Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring

AIMS/INTRODUCTION: There is little information regarding how to use insulin degludec (D) when diabetic patients are preparing for total colonoscopy (TCS). MATERIALS AND METHODS: A total of 12 patients with type 2 diabetes treated with insulin D and scheduled to undergo TCS were enrolled in the prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeishi, Soichi, Mori, Akihiro, Fushimi, Nobutoshi, Hachiya, Hiroki, Yumura, Takayuki, Ito, Shun, Shibuya, Takashi, Ohashi, Noritsugu, Kawai, Hiromi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847892/
https://www.ncbi.nlm.nih.gov/pubmed/27330724
http://dx.doi.org/10.1111/jdi.12409
_version_ 1782429276982738944
author Takeishi, Soichi
Mori, Akihiro
Fushimi, Nobutoshi
Hachiya, Hiroki
Yumura, Takayuki
Ito, Shun
Shibuya, Takashi
Ohashi, Noritsugu
Kawai, Hiromi
author_facet Takeishi, Soichi
Mori, Akihiro
Fushimi, Nobutoshi
Hachiya, Hiroki
Yumura, Takayuki
Ito, Shun
Shibuya, Takashi
Ohashi, Noritsugu
Kawai, Hiromi
author_sort Takeishi, Soichi
collection PubMed
description AIMS/INTRODUCTION: There is little information regarding how to use insulin degludec (D) when diabetic patients are preparing for total colonoscopy (TCS). MATERIALS AND METHODS: A total of 12 patients with type 2 diabetes treated with insulin D and scheduled to undergo TCS were enrolled in the present study. A continuous glucose monitoring device was attached to each patient for 4 days, from two evenings before TCS to the morning after the procedure. The patients fasted for 24 h, starting after 18.00 h the day before TCS. Insulin D was only discontinued the morning of the day TCS was carried out. RESULTS: No patients experienced hypoglycemia during the daytime fasting period (08.00–18.00 h the day of TCS); the hypoglycemic index, mean glucose level, and standard deviation were 0, 141.3 ± 31.5 mg/dL and 15.6 ± 6.5 mg/dL. The mean glucose level and standard deviation during the daytime fasting period were significantly lower than during the daytime control period (08.00–18.00 h the day before TCS; P = 0.003, P = 0.001, respectively). The mean fasting glucose and fasting plasma glucose levels were significantly correlated (r = 0.78, P = 0.002), as were both the mean glucose level and standard deviation during the daytime control period, and the change in the mean glucose level (fasting period minus control period; r = −0.79, P = 0.002, and r = −0.69, P = 0.01, respectively). CONCLUSIONS: Patients can safely undergo TCS when insulin D is discontinued only once on the day of the procedure.
format Online
Article
Text
id pubmed-4847892
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48478922016-06-21 Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring Takeishi, Soichi Mori, Akihiro Fushimi, Nobutoshi Hachiya, Hiroki Yumura, Takayuki Ito, Shun Shibuya, Takashi Ohashi, Noritsugu Kawai, Hiromi J Diabetes Investig Articles AIMS/INTRODUCTION: There is little information regarding how to use insulin degludec (D) when diabetic patients are preparing for total colonoscopy (TCS). MATERIALS AND METHODS: A total of 12 patients with type 2 diabetes treated with insulin D and scheduled to undergo TCS were enrolled in the present study. A continuous glucose monitoring device was attached to each patient for 4 days, from two evenings before TCS to the morning after the procedure. The patients fasted for 24 h, starting after 18.00 h the day before TCS. Insulin D was only discontinued the morning of the day TCS was carried out. RESULTS: No patients experienced hypoglycemia during the daytime fasting period (08.00–18.00 h the day of TCS); the hypoglycemic index, mean glucose level, and standard deviation were 0, 141.3 ± 31.5 mg/dL and 15.6 ± 6.5 mg/dL. The mean glucose level and standard deviation during the daytime fasting period were significantly lower than during the daytime control period (08.00–18.00 h the day before TCS; P = 0.003, P = 0.001, respectively). The mean fasting glucose and fasting plasma glucose levels were significantly correlated (r = 0.78, P = 0.002), as were both the mean glucose level and standard deviation during the daytime control period, and the change in the mean glucose level (fasting period minus control period; r = −0.79, P = 0.002, and r = −0.69, P = 0.01, respectively). CONCLUSIONS: Patients can safely undergo TCS when insulin D is discontinued only once on the day of the procedure. John Wiley and Sons Inc. 2015-09-06 2016-05 /pmc/articles/PMC4847892/ /pubmed/27330724 http://dx.doi.org/10.1111/jdi.12409 Text en © 2015 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Takeishi, Soichi
Mori, Akihiro
Fushimi, Nobutoshi
Hachiya, Hiroki
Yumura, Takayuki
Ito, Shun
Shibuya, Takashi
Ohashi, Noritsugu
Kawai, Hiromi
Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring
title Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring
title_full Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring
title_fullStr Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring
title_full_unstemmed Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring
title_short Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring
title_sort evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847892/
https://www.ncbi.nlm.nih.gov/pubmed/27330724
http://dx.doi.org/10.1111/jdi.12409
work_keys_str_mv AT takeishisoichi evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring
AT moriakihiro evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring
AT fushiminobutoshi evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring
AT hachiyahiroki evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring
AT yumuratakayuki evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring
AT itoshun evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring
AT shibuyatakashi evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring
AT ohashinoritsugu evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring
AT kawaihiromi evaluationofsafetyofinsulindegludeconundergoingtotalcolonoscopyusingcontinuousglucosemonitoring